1795 Share Price Performance
NT$294.00
16.50 (5.95%)
51.0% undervalued intrinsic discount
NT$600.00
Fair Value
Price NT$294.00
AnalystHighTarget NT$600.00
AnalystConsensusTarget NT$378.20
AnalystLowTarget NT$250.00
Fair ValueNT$600.00
Share Pricen/a
Lotus Pharmaceutical Co., Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
1795 Community Narratives
AN
Fair Value NT$600 51.0% undervalued intrinsic discount
Hybrid Pipeline Expansion Will Harness Aging Trends Amid Cost Headwinds
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value NT$378.2 22.3% undervalued intrinsic discount
Analysts Reaffirm Lotus Pharmaceutical Price Target Amid Stable Growth and Profitability Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value NT$215 36.7% overvalued intrinsic discount
Trade And Regulation Will Shrink Margins Yet Southeast Asia Aids
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Analysts Reaffirm Lotus Pharmaceutical Price Target Amid Stable Growth and Profitability Outlook
Key Takeaways Strategic acquisitions and alliances are bolstering Lotus Pharmaceutical's growth and diversification, particularly in Southeast Asia. In-house production and a strong product pipeline are enhancing profitability and driving revenue and earnings growth.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
NT$378.2
22.3% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
36.17% p.a.
Profit Margin
22.95%
Future PE
10.18x
Share price in 2028
NT$439.93
Hybrid Pipeline Expansion Will Harness Aging Trends Amid Cost Headwinds
Key Takeaways Seamless business integrations and operational execution are fueling rapid growth and market dominance in Southeast Asia, with long-term revenue and market share expansion potential. Margin growth, a strategic pipeline, and strong cash flow position Lotus for global expansion, innovation, and leadership in both generic and high-value pharmaceutical markets.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
NT$600
51.0% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
7.49% p.a.
Profit Margin
23.72%
Future PE
31.72x
Share price in 2028
NT$696.74
Trade And Regulation Will Shrink Margins Yet Southeast Asia Aids
Key Takeaways Expanding into emerging markets and investing in complex generics position Lotus for growth, but rising regulatory, trade, and supply chain risks threaten margins and stability. Heavy reliance on key products and exposure to patent expiries, competition, and evolving drug technologies may cause future revenue volatility and limit long-term earnings potential.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
NT$215
36.7% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
2.29% p.a.
Profit Margin
18.41%
Future PE
16.99x
Share price in 2028
NT$249.67
Snowflake Analysis
Lotus Pharmaceutical Co., Ltd. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 17.99
- 58.26%
- 25.36%
- 35.9%
About 1795
- Founded
- 1966
- Employees
- n/a
- CEO
- WebsiteView website
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. In addition, it offers management consultancy services; pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan.
